Stockscreener 앱 받기
45.59
0.93%
-0.43
시간 외 거래:
45.62
0.03
+0.07%
전일 마감가:
$46.02
열려 있는:
$45.49
하루 거래량:
16.29M
Relative Volume:
1.14
시가총액:
$92.80B
수익:
$48.03B
순이익/손실:
$6.05B
주가수익비율:
15.39
EPS:
2.9615
순현금흐름:
$15.30B
1주 성능:
+6.47%
1개월 성능:
+0.31%
6개월 성능:
-9.85%
1년 성능:
-17.78%
1일 변동 폭
$45.38
$46.59
1주일 범위
$42.52
$46.66
52주 변동 폭
$42.52
$63.33
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
45.59 | 93.69B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
907.68 | 802.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.86 | 448.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
216.04 | 374.44B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
125.01 | 237.66B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.86 | 206.04B | 63.99B | 19.05B | 14.72B | 7.5596 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Bristol-Myers Squibb: Way Too Cheap At 7x P/E (NYSE:BMY) - Seeking Alpha
TIAA Trust National Association Reduces Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth - Seeking Alpha
BioNTech Boosts 2025 Outlook as Cancer Drug Alliance with Bristol Myers Squibb Takes Aim at Merck’s Keytruda - Tekedia
Pulmonary Fibrosis Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Bristol-Myers Squibb, PureTech Health, Sarepta Therapeutics, Boehringer Ingelheim, A - Barchart.com
Balanced Outlook on Bristol-Myers Squibb: Strong Q3 Performance Amid ADEPT-2 Trial Concerns - TipRanks
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership - inkl
Bristol Myers Squibb to present Camzyos efficacy data at AHA scientific sessions - Investing.com
Bristol-Myers Squibb stock rises 7% after clean earnings beat By Investing.com - Investing.com Nigeria
United States Vitiligo Forecast Report 2025: A $320+ Million Market by 2033 Featuring Incyte, BMS, Clinuvel Pharmaceuticals, Astellas Pharma, Baxter, Pfizer, Dr. Reddy's LaboratoriesResearchAndMarkets.com - Business Wire
US Cancer Immunotherapy Forecast and Company Analysis Report 2025-2033 Featuring Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Pfizer, Novartis, Johnson & Johnson, Eli Lily Co, Seattle GeneticsResearchAndMarkets.com - FinancialContent
Bristol-Myers Squibb stock rises 7% after clean earnings beat - Investing.com
Cleveland-Cliffs, Meta And Rocket On CNBC's 'Final Trades' - Benzinga
Verity Asset Management Inc. Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025 - Business Wire
BioNTech raises 2025 revenue guidance after Bristol Myers deal By Investing.com - Investing.com Nigeria
BioNTech raises 2025 revenue guidance after Bristol Myers deal - Investing.com
BioNTech lifts 2025 revenue guidance on BMS partnership payment - Reuters
BioNTech Raises Sales Outlook on Boost from Bristol Payments - Bloomberg.com
Bristol Myers Squibb Co Announces $7 Billion Cash Tender Offers - TradingView
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes - The AI Journal
Published on: 2025-11-02 22:42:16 - newser.com
How Bristol Myers Squibb Company (BRM) stock moves in volatile trading sessionsQuarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Syverson Strege & Co Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Assetmark Inc. Lowers Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
What’s the recovery path for long term holders of Bristol Myers Squibb Company Equity RightTrade Signal Summary & Technical Pattern Alert System - newser.com
Bristol-Myers Squibb Company (NYSE:BMY) Q3 2025 Earnings Call Transcript - Insider Monkey
Can Bristol Myers Squibb Company stock hit record highs againExit Point & Entry Point Confirmation Signals - newser.com
Bristol Myers Squibb Co. Hits New 52-Week Low at $42.52 - Markets Mojo
Bristol Myers Squibb Company recovery potential after sell offWeekly Market Report & Risk Controlled Daily Trade Plans - newser.com
Is Bristol Myers Squibb Company Celegne Contingent stock a fit for income portfolios2025 Market Overview & Comprehensive Market Scan Insights - newser.com
Bristol-Myers Squibb Company (BMY.MX) stock price, news, quote and history - Yahoo! Finance UK
Bristol Myers Squibb (NYSE:BMY) Posts Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Bristol Myers Squibb Stock Hits Day High with 7.09% Surge - Markets Mojo
S&P 500 Falls 0.99% Amid 1,651 Advancing Stocks; Bristol Myers Soars 7.09% - Markets Mojo
Bristol-Myers Squibb Tops Forecasts But Leaves Questions Unanswered - Finimize
Germ Cell Tumors Market: Epidemiology, Therapies, Companies – DelveInsight | Featuring Takeda, Novartis, Bristol Myers Squibb, Merck & Co., Roche, and Bayer - Barchart.com
Retirement Systems of Alabama Has $60.37 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
New launches focus of latest financial prints at BMS, Merck & Co. - FirstWord Pharma
Bristol-Myers Squibb Company Confirms Efficacy and Safety of Sotyktu for Psoriatic Arthritis and Lupus with New Long-Term Data - Insider Monkey
Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings: Revenue Surpasse - GuruFocus
Bristol-Myers Squibb Shares Rally on Strong Quarterly Performance - AD HOC NEWS
Will Bristol Myers Squibb Company (BRM) stock beat growth indexesBuy Signal & Momentum Based Trading Signals - newser.com
Bristol-Myers Squibb Company (BMY) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Research Alert: CFRA Keeps Buy View On Shares Of Bristol-myers Squibb Company - 富途牛牛
Bristol-Myers Squibb Company (BMY) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Bristol-Myers Sets $160 Million Tax Reserve for Transfer Pricing - news.bloombergtax.com
Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance
Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript Summary - 富途牛牛
Bladder Cancer MarketGlobal and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson - Yahoo Finance
BRISTOL MYERS SQUIBB CO SEC 10-Q Report - TradingView
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.88%
0.81%
자본화:
|
볼륨(24시간):